ZEISS Quality Innovations Worldwide

All events now in one video.

Insurance in Life Science: From risk to resilience

Are you visiting The Future of Swedish & Danish Life Science event in Lund 23 April? Don't miss the Gallagher seminar on Risk and Insurance in the Life Sciences sector.

A healthy society requires more than a new pill

Sarah Lidé on how medicines are essential – but a sustainable approach to healthy societies also depends on prevention and behavioural change

“BioArctic is Leqembi, but also much more”

What once began as a small Swedish biotech company has grown into a fully fledged pharmaceutical company with global reach. At the helm is Gunilla Osswald, who ...

More than 150 jobs cut as Merck scales back vaccin production

Merck & Co, known as MSD in Europe, is hitting the brakes following a sharp decline in demand for its HPV vaccine Gardasil. Production at its facility in Durham...

Simple Material Analysis – From Classical to AI

Free webinar March 05, 2026, 09:00 - 09:45 AM / 05:00 - 05:45 PM (CET).

Novo Nordisk strengthens board after turbulent year

Changes to Novo Nordisk’s board continue. Following last year’s sweeping restructuring, the Danish obesity drugmaker is now nominating two new directors with ex...

National cord blood bank resumes collection

The collection of umbilical cord blood is now resuming during planned caesarean sections at Östra Hospital in Gothenburg. The blood remaining in the placenta an...

Upcoming training: MD software process design based on IEC 62304

Together with Intertek Academy, we offer a 2-day course in Stockholm, Sweden, covering Medical device software process design based on IEC 62304. This course is...

FDA leaders seek to scrap two-study requirement

A single pivotal study may be sufficient to secure approval for a new medicine in the United States. That is the message delivered by FDA Commissioner Marty Mak...

New treatment recommended for children with brain tumours

The European Medicines Agency has recommended conditional approval of a new targeted treatment for children with the brain tumour pediatric low-grade glioma.

Paul Chaplin steps down as CEO of Bavarian Nordic

Danish vaccine company Bavarian Nordic’s CEO, Paul Chaplin, is stepping down from his position for personal reasons.

Explore 3D Testing of Deformation and Motions

Powerful measurement capabilities with the new ZEISS ARAMIS 1.

Anna Törner: ”Smal, till vilket pris?”

"Man kan tycka vad man vill om beslutet, men det är i varje fall inte fegt". Så skriver Anna Törner i en krönika med utgångspunkt i TLV:s beslut om att Wegovy i...

Björn Arvidsson: ”As uncertainty grows, clarity becomes a strength”

Sweden has all the prerequisites to be a strong life science nation. But in a time of geopolitical tension, shorter value chains and growing demands for resilie...

International medical graduates leave Sweden in high numbers

Three years after completing their studies, 46 percent of international doctoral students who graduated in the medical field had left the country. This is shown...

Painkiller cuts recurrence risk by more than 50% – national guidelines updated

Sweden’s national guidelines for colon and rectal cancer have been updated — just nine months after the previous revision. The move follows new Swedish research...

ZEISS är redo för fackmässan Elmia Verktygsmaskiner

Som besökare kan man träffa experter från ZEISS försäljnings- och applikationsteam.

Bioscience – Groundbreaking Research & Diagnostics: Stockholm

A cluster contribution to European life science innovation and competitiveness?

New antibody aims to slow kidney damage – “It’s kind of cool”

For 25 years, Marie Jeansson has studied the kidney and its blood vessels. She is now working on developing a drug intended to slow down chronic kidney disease.

Genovis ramps up in ADC technology: “An area where we’re seeing very strong interest”

With new products and an expanded licensing agreement in hand Genovis now has a partly new focus for its operations: ADCs – or antibody‑drug conjugates.

We are expanding our English-language coverage

Over a period of four weeks, one of Life Science Sweden's regular daily newsletters is being published entirely in English. The aim is to meet increasing demand...

Anna Törner: ”Drug prices – an important driver of innovation”

We live under the illusion that no price is too high when it comes to health, but that simply isn’t true, writes Anna Törner.